|
Name |
Cyclo(Ile-Leu-Leu-Leu-Leu-)
|
Molecular Formula | C30H55N5O5 | |
IUPAC Name* |
(3S,6S,9S,12S,15S)-3-[(2S)-butan-2-yl]-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone
|
|
SMILES |
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CC(C)C)CC(C)C)CC(C)C
|
|
InChI |
InChI=1S/C30H55N5O5/c1-11-20(10)25-30(40)34-23(14-18(6)7)28(38)32-21(12-16(2)3)26(36)31-22(13-17(4)5)27(37)33-24(15-19(8)9)29(39)35-25/h16-25H,11-15H2,1-10H3,(H,31,36)(H,32,38)(H,33,37)(H,34,40)(H,35,39)/t20-,21-,22-,23-,24-,25-/m0/s1
|
|
InChIKey |
MEJHOHNWGFEFFZ-OOPVGHQCSA-N
|
|
Synonyms |
Cyclo(Ile-Leu-Leu-Leu-Leu-); Cyclo-(L-Ile-L-Leu-L-Leu-L-Leu-L-Leu)
|
|
CAS | NA | |
PubChem CID | 102342363 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 565.8 | ALogp: | 5.3 |
HBD: | 5 | HBA: | 5 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 146.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 40 | QED Weighted: | 0.275 |
Caco-2 Permeability: | -5.135 | MDCK Permeability: | 0.00007150 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.664 |
Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.993 |
30% Bioavailability (F30%): | 0.632 |
Blood-Brain-Barrier Penetration (BBB): | 0.034 | Plasma Protein Binding (PPB): | 84.32% |
Volume Distribution (VD): | 0.553 | Fu: | 2.10% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.03 |
CYP2C19-inhibitor: | 0.295 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.415 | CYP2C9-substrate: | 0.078 |
CYP2D6-inhibitor: | 0.05 | CYP2D6-substrate: | 0.089 |
CYP3A4-inhibitor: | 0.8 | CYP3A4-substrate: | 0.15 |
Clearance (CL): | 4.302 | Half-life (T1/2): | 0.335 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.834 |
Drug-inuced Liver Injury (DILI): | 0.051 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.692 | Maximum Recommended Daily Dose: | 0.142 |
Skin Sensitization: | 0.048 | Carcinogencity: | 0.092 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.038 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004731 | 0.622 | D0K7NQ | 0.364 | ||||
ENC005469 | 0.519 | D0J7XL | 0.346 | ||||
ENC003175 | 0.519 | D02SBQ | 0.318 | ||||
ENC002910 | 0.500 | D0O3YF | 0.317 | ||||
ENC001983 | 0.485 | D0L9HX | 0.313 | ||||
ENC002373 | 0.441 | D0M3FJ | 0.309 | ||||
ENC002515 | 0.402 | D09OOV | 0.286 | ||||
ENC000990 | 0.400 | D08FJL | 0.281 | ||||
ENC002212 | 0.400 | D0Q3BV | 0.278 | ||||
ENC002514 | 0.388 | D0D8XY | 0.271 |